Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 13, 2008

Dutch Center and GeneGo to Collaborate on Toxicity Testing

  • GeneGo will help the Netherlands Toxicogenomics Center (NTC) in its integrated systems toxicology approach to risk assessment. This five-year, 25 million, multiparty program is aimed at developing omics-based screens for the evaluation of chemical safety in humans and the possible replacment or reduction of animal experiments.

    The NTC will use GeneGo’s MetaCore and MetaDrug systems biology data analysis platform to identify the key biological functions and pathways contributing to the adverse effects of xenobiotic exposure. They will coordinate, visualize, and interpret chemical, metabolomic, proteomic, and gene expression data.

    GeneGo will work within the bioinformatics group of the NTC to build predictive models using its Functional Descriptor technology. The goal is to identify as early as possible adverse effects in animals from short-term in vivo experiments or during in vitro investigations.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »